BR112022023376A2 - Uso de fenilacetamidas possuindo atividade antagonística de receptor de p2x4 para o tratamento de certos distúrbios oculares - Google Patents

Uso de fenilacetamidas possuindo atividade antagonística de receptor de p2x4 para o tratamento de certos distúrbios oculares

Info

Publication number
BR112022023376A2
BR112022023376A2 BR112022023376A BR112022023376A BR112022023376A2 BR 112022023376 A2 BR112022023376 A2 BR 112022023376A2 BR 112022023376 A BR112022023376 A BR 112022023376A BR 112022023376 A BR112022023376 A BR 112022023376A BR 112022023376 A2 BR112022023376 A2 BR 112022023376A2
Authority
BR
Brazil
Prior art keywords
treatment
possessing
antagonistic activity
receptor antagonistic
phenylacethamides
Prior art date
Application number
BR112022023376A
Other languages
English (en)
Inventor
Bäurle Stefan
Schubert William
Nagel Jens
Terjung Carsten
Finis David
Yiu Samuel
Lin Hui
Chen Minjie
Seo Stefanie
Original Assignee
Bayer Ag
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Univ Johns Hopkins filed Critical Bayer Ag
Publication of BR112022023376A2 publication Critical patent/BR112022023376A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE FENILACETAMIDAS POSSUINDO ATIVIDADE ANTAGONÍSTICA DE RECEPTOR DE P2X4 PARA O TRATAMENTO DE CERTOS DISTÚRBIOS OCULARES. A presente invenção refere-se ao uso de antagonistas de P2X4 para o tratamento de síndrome do olho seco, mais em particular compostos de N-fenilacetamida substituída de Fórmula geral (I), composições farmacêuticas e combinações compreendendo os referidos compostos para uso no tratamento ou profilaxia de síndrome do olho seco e, em particular, olho seco, dor neuropática ocular, dor ocular de pós-operatório e de trauma ocular.
BR112022023376A 2020-06-30 2021-06-28 Uso de fenilacetamidas possuindo atividade antagonística de receptor de p2x4 para o tratamento de certos distúrbios oculares BR112022023376A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20183306 2020-06-30
EP21151884 2021-01-15
US202163202797P 2021-06-24 2021-06-24
PCT/EP2021/067714 WO2022002860A1 (en) 2020-06-30 2021-06-28 Use of n-phenylacetamides having p2x4 receptor antagonistic activity for treating certain ocular disorders

Publications (1)

Publication Number Publication Date
BR112022023376A2 true BR112022023376A2 (pt) 2023-01-10

Family

ID=76744841

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023376A BR112022023376A2 (pt) 2020-06-30 2021-06-28 Uso de fenilacetamidas possuindo atividade antagonística de receptor de p2x4 para o tratamento de certos distúrbios oculares

Country Status (10)

Country Link
US (1) US20230270729A1 (pt)
EP (1) EP4171744A1 (pt)
JP (1) JP2023533496A (pt)
KR (1) KR20230031308A (pt)
CN (1) CN115989218A (pt)
AU (1) AU2021301158A1 (pt)
BR (1) BR112022023376A2 (pt)
CA (1) CA3188311A1 (pt)
IL (1) IL299383A (pt)
WO (1) WO2022002860A1 (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2789641C (en) 2009-02-16 2018-03-13 Nippon Chemiphar Co., Ltd. Diazepinedione derivative
WO2012008478A1 (ja) 2010-07-13 2012-01-19 日本ケミファ株式会社 Ｐ２ｘ４受容体拮抗剤
CN108863959B (zh) 2012-01-13 2021-11-30 日本化学药品株式会社 P2x4受体拮抗剂
ES2753422T3 (es) 2013-07-12 2020-04-08 Nippon Chemiphar Co Antagonista de receptor P2X4
JP6357475B2 (ja) 2013-07-12 2018-07-11 日本ケミファ株式会社 Ｐ２ｘ４受容体拮抗剤
CN107848974A (zh) 2015-06-10 2018-03-27 拜耳制药股份公司 芳族磺酰胺衍生物
RS61012B1 (sr) 2016-05-03 2020-11-30 Bayer Pharma AG Aromatični derivati sulfonamida
WO2018104305A1 (en) 2016-12-09 2018-06-14 Bayer Pharma Aktiengesellschaft Field of application of the invention
WO2018104307A1 (en) 2016-12-09 2018-06-14 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives and their use as anatagon i sts or negative allosteric modulators of p2x4
US20230183182A1 (en) 2019-11-29 2023-06-15 Wuhan Ll Science And Technology Development Co., Ltd. Compound containing benzene ring and application thereof

Also Published As

Publication number Publication date
IL299383A (en) 2023-02-01
CA3188311A1 (en) 2022-01-06
AU2021301158A1 (en) 2022-12-15
JP2023533496A (ja) 2023-08-03
US20230270729A1 (en) 2023-08-31
WO2022002860A1 (en) 2022-01-06
CN115989218A (zh) 2023-04-18
KR20230031308A (ko) 2023-03-07
EP4171744A1 (en) 2023-05-03

Similar Documents

Publication Publication Date Title
WO2019191092A8 (en) Compounds for treating huntington's disease
BR112018072549A2 (pt) derivados de sulfonamida aromática
BR112017012327A8 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
MX2021004431A (es) Procesos novedosos.
BRPI0619153B8 (pt) derivados de 4-amino-pirroltriazina substituída, e composição farmacêutica
CL2019002511A1 (es) Composición farmacéutica que comprende selexipag.
BR112017017009A2 (pt) usos de um sequestrante de formaldeído e de uma composição farmacêutica, métodos para impedir, adiar, retardar ou diminuir a transformação de um composto e para tratar câncer, e, composição farmacêutica.
BR0313041A (pt) Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
BR112019001615A2 (pt) métodos e composições para tratar mielofibrose
CL2020001762A1 (es) Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464)
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
BRPI0918868B8 (pt) compostos moduladores do receptor de nmda e composições compreendendo os mesmos
BR112022019991A2 (pt) Compostos, composição farmacêutica compreendendo o mesmo, e usos dos mesmos
BRPI0612125A2 (pt) compostos da fórmula (i), processo para a fabricação destes, composto da fórmula iiia, composições farmacêuticas, método para o tratamento e/ou profilaxia de doenças associadas à modulação dos receptores cb1 e uso de compostos
BR112022010112A2 (pt) Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica
BR112015019039A8 (pt) compostos antagonistas de integrina fluorados, composição farmacêutica compreendendo ditos compostos e uso destes para tratar ou prevenir uma doença ou condição mediada por uma av integrina
MX2021005945A (es) Ureas ciclicas.
BR112015028235A2 (pt) (ciano-dimetil-metil)-isoxazóis e -[1,3,4]tiadiazóis
BR112021026397A2 (pt) Antagonista de ep2
ECSP22040921A (es) Composición farmacéutica que comprende selexipag
BR112022023376A2 (pt) Uso de fenilacetamidas possuindo atividade antagonística de receptor de p2x4 para o tratamento de certos distúrbios oculares
BRPI0801239A2 (pt) uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica